Nootropics Index - Save on smarter supplements
Nootropics>Botanical & herbal supplements>Magnolia Bark
Botanical & herbal supplements

Magnolia Bark

Magnolia officinalis bark extract

Magnolia Bark usually means Magnolia officinalis bark extract, often standardized for honokiol and magnolol. The best human stress data are small trials of a proprietary Magnolia/Phellodendron blend, not standalone bark: one 4-week study used 500 mg/day and one 6-week pilot used 250 mg three times daily. It is best framed as a calming/stress-support botanical with limited human evidence, not a strong nootropic. Safety review should cover sedation, benzodiazepine or sedative-drug combinations, blood thinners, diabetes drugs, pregnancy/lactation, and whether the product states honokiol/magnolol standardization.

CalmRelaxationStress ResilienceMood SupportStandardized ExtractTraditional UseLimited Human Evidence
Updated July 2026/6 min read/11 citations
Prepared by the NootropicsIndex editorial team.Method: prioritize cited human research and official safety or regulatory sources; compare retailer-listed prices without endorsing products.Affiliate disclosure
01

What is it?

What it is

1

Magnolia Bark usually refers to bark extract from Magnolia officinalis, known in traditional Chinese herbal practice as Hou Po. Supplements are often standardized for honokiol and magnolol, two biphenolic marker compounds.

Blend evidence is not standalone bark proof5
The strongest human stress evidence uses a proprietary Magnolia/Phellodendron blend. That makes the evidence useful for context, but weaker for products that contain only Magnolia bark or do not disclose honokiol and magnolol standardization.
02

Names, aliases and forms

Common NameMagnolia Bark
Scientific NameMagnolia officinalis
Traditional NameHou Po
Spelling VariantHoupu magnolia
Extract NameMagnolia bark extract
Active ConstituentsHonokiol; Magnolol
Pubchem CidsHonokiol CID 72303; Magnolol CID 72300
03

Potential effects and evidence map

Magnolia officinalis bark contains honokiol and magnolol, constituents with preclinical GABAergic, anti-inflammatory and other pharmacology. Human evidence relevant to nootropic-style use is limited and mostly comes from proprietary Magnolia/Phellodendron blends studied for stress, cortisol, mood state, rest quality and stress-eating outcomes. The page should avoid presenting standalone Magnolia bark as proven for stress-related tension, rest, focus or cognition, and should emphasize product standardization plus sedative and drug-combination cautions.

Effect domainMagnitudeGrade
Stress resilience5
CumulativeConfidence: Medium

Small Magnolia/Phellodendron blend studies suggest modest stress and cortisol-related benefits over 4-6 weeks.

Note Evidence is formulation-specific and should not be generalized to all standalone bark products.

2/5
C
Calm / relaxation2
Acute + cumulativeConfidence: Low

Magnolia has calming rationale from traditional use, honokiol/magnolol pharmacology, and limited blend trials.

Note Avoid strong stress-support language; MSK notes human calming data for Magnolia itself are lacking.

2/5
C
Mood / wellbeing5
CumulativeConfidence: Low

A 4-week blend study reported improved mood-state measures, including tension, fatigue, confusion and vigor.

Note The trial was small and involved a proprietary blend.

2/5
C
Focus / attention2
UnknownConfidence: High

Magnolia Bark is not supported as a focus, attention or productivity nootropic.

Note Do not infer cognitive enhancement from calming or stress findings.

0/5
E
04

Typical dosages and timing

Typical
500-750 mg/day
Not a recommendation
Lower bound
500 mg
Profile value
Upper bound
750 mg
Profile value
human studies6500-750 mg/day

The main human blend studies used 500 mg/day for 4 weeks or 250 mg three times daily for 6 weeks. For standalone Magnolia bark, use product-specific standardization and avoid assuming that more bark equals stronger or safer effects.

05

Timing & effect horizon

Effect horizonCumulative
Cumulative
Study window5Cumulative
4 weeks
Pilot window7Cumulative
6 weeks
Trial windows were measured in weeks5

Human outcomes were assessed after four to six weeks. Acute calming may be marketed by sellers, but the available human trial evidence is better interpreted as short-term repeated-use data.

06

Safety, side effects and risk profile

Sedation and drug-combination caution2
Magnolia Bark may add to benzodiazepine or sedative-drug effects. People using sedating drugs, alcohol-heavy routines, or tasks requiring alertness should be cautious until individual response is known.
Sedation / impairment2
Confidence: Medium

Magnolia may add to benzodiazepine or sedative-drug effects; avoid driving or hazardous tasks until individual response is known.

Note MSK lists rest/sedative-drug combinations as a do-not-take caution.

3/5
C
Pregnancy / lactation caution2
Confidence: High

Avoid during pregnancy, lactation or attempts to conceive because human safety data are insufficient and sedative botanicals are not low-risk default choices.

Note No specific reproductive safety margin is established.

4/5
E
Evidence uncertainty7
Confidence: High

Human studies are small, often proprietary and blend-based, so standalone Magnolia bark claims remain uncertain.

Note Use this domain to keep claims scoped to the available human evidence.

3/5
C
GI discomfort5
Confidence: Low

Digestive tolerance appears acceptable in small trials, but product-specific tolerability varies.

Note Not a dominant risk compared with sedation and combined-uses.

1/5
E
Headache / dizziness2
Confidence: Low

Start cautiously because calming botanicals can cause lightheadedness or next-day sluggishness in sensitive users.

Note General tolerability caution; not a strong trial signal.

2/5
E
possible additive effects2

MSK lists blood thinners and diabetes drugs as review-first categories because Magnolia bark extract may increase bleeding risk or enhance glucose-lowering effects. The clinical relevance is uncertain, but the caution belongs on the page.

CYP / P-gp / UGT9

Honokiol and Magnolia constituents have in vitro signals involving CYP450, UGT and P-gp pathways. This does not predict a specific clinical effect by itself, but it supports extra caution with narrow-therapeutic-index drugs.

insufficient safety data2

Avoid Magnolia Bark during pregnancy, lactation, or attempts to conceive unless a qualified clinician specifically reviews the situation. Human reproductive safety data are not adequate for casual use.

contact allergy reports11

Contact dermatitis has been reported with cosmetics containing Magnolia officinalis bark extract. Oral supplement data are limited, but rash or allergic-type symptoms should prompt discontinuation and review.

07

Practical buying and quality notes

  • Prefer products that disclose Magnolia officinalis bark, extraction type, honokiol and magnolol standardization, serving size, and third-party contaminant testing. Avoid vague proprietary blends that hide the Magnolia dose.4
  • If a product combines Magnolia with Phellodendron, lemon balm, GABA, melatonin or other calming ingredients, do not attribute the full effect to Magnolia Bark. Compare the full formula and total sedative load.7
08

FAQ

Is Magnolia Bark a nootropic?

2

Not in the classic focus-enhancer sense. It is better viewed as a calming botanical with limited stress and mood evidence, mostly from blend studies.

What dose has human evidence?

6

The relevant human blend studies used 500 mg/day or 250 mg three times daily. Those doses apply to the studied Magnolia/Phellodendron blend, not automatically to every standalone Magnolia bark extract.

Can Magnolia Bark support nighttime rest?

7

Possibly for some stressed users, but rest evidence is limited and mostly secondary to blend studies. Treat it as cautious relaxation support rather than a proven rest treatment.

Who should be most cautious?

2

Pregnant or lactating users, people using sedating drugs, blood thinners or diabetes drugs, and anyone with complex health conditions should get qualified review before use.

09

References

  1. NCBI Taxonomy. Magnolia officinalis. Taxonomy ID 85864.
  2. Memorial Sloan Kettering Cancer Center. Magnolia officinalis. About Herbs.
  3. PubChem. Compound Summary for CID 72303, Honokiol.
  4. PubChem. Compound Summary for CID 72300, Magnolol.
  5. Talbott SM, Talbott JA, Pugh M. Effect of Magnolia officinalis and Phellodendron amurense (Relora) on cortisol and psychological mood state in moderately stressed subjects. J Int Soc Sports Nutr. 2013;10(1):37.
  6. Talbott SM, Talbott JA, Pugh M. Full text: Relora study methods and dose details.
  7. Kalman DS, Feldman S, Feldman R, Schwartz HI, Krieger DR, Garrison R. Effect of a proprietary Magnolia and Phellodendron extract on stress levels in healthy women: a pilot, double-blind, placebo-controlled clinical trial. Nutr J. 2008;7:11.
  8. Garrison R, Chambliss WG. Effect of a proprietary Magnolia and Phellodendron extract on weight management: a pilot, double-blind, placebo-controlled clinical trial. Altern Ther Health Med. 2006;12(1):50-54.
  9. Jeong HU, Kong TY, Kwon SS, Hong SW, Yeon SH, Choi JH, Lee JY, Cho YY, Lee HS. Effect of honokiol on cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in human liver microsomes. Molecules. 2013;18(9):10681-10693.
  10. Han HK, Van Anh LT. Modulation of P-glycoprotein expression by honokiol, magnolol and 4-O-methylhonokiol, the bioactive components of Magnolia officinalis. Anticancer Res. 2012;32(10):4445-4452.
  11. Ghys K, De Palma A, Vandevenne A, Werbrouck J, Goossens A. Magnolia officinalis bark extract, a recently identified contact allergen in anti-ageing cosmetics. Contact Dermatitis. 2015;73(2):130-132.
Note

This page is informational and summarizes available evidence. It is not medical advice, a recommendation, or a substitute for guidance from a qualified clinician.